clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Braden B The best and worst treatments for Helicobacter pylori. 2015 BMJ pmid:26290321
Fujimura S et al. Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices. 2015 J. Infect. Chemother. pmid:26162777
Cavkaytar S et al. Clarithromycin regresses endometriotic implants in rat endometriosis model. 2015 J Obstet Gynaecol pmid:26156575
Bai P et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. 2015 J Dig Dis pmid:26147515
Nie W et al. Species Identification and Clarithromycin Susceptibility Testing of 278 Clinical Nontuberculosis Mycobacteria Isolates. 2015 Biomed Res Int pmid:26146620
Kozan G et al. Effect of systemic clarithromycin and prednisolone on histamine-induced otitis media in guinea pigs. 2015 Acta Otolaryngol. pmid:26143935
Ferro BE et al. Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. 2015 J. Antimicrob. Chemother. pmid:26142475
Honda M et al. Preoperative vs Postoperative Eradication of Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial. 2015 J. Am. Coll. Surg. pmid:26141464
Matsumoto T et al. Mycobacterium fortuitum thoracic empyema: A case report and review of the literature. 2015 J. Infect. Chemother. pmid:26139179
Losurdo G et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by 'geographical weighting'. 2015 Int. J. Clin. Pract. pmid:26138290
Reveiz L and Cardona AF Antibiotics for acute laryngitis in adults. 2015 Cochrane Database Syst Rev pmid:26002823
Zhang T Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. 2015 Eur J Pharm Sci pmid:26116278
Fraser LA et al. Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study. 2015 Ann Pharmacother pmid:25429094
Lee SJ et al. Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice. 2015 PLoS ONE pmid:26114656
Ahmed S and Atia NN Simultaneous determination of triple therapy for Helicobacter pylori in human plasma by reversed phase chromatography with online wavelength switching. 2015 Spectrochim Acta A Mol Biomol Spectrosc pmid:25459696
Prapitpaiboon H et al. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. 2015 Asian Pac. J. Cancer Prev. pmid:26028098
Tojima I et al. Anti-inflammatory effects of a novel non-antibiotic macrolide, EM900, on mucus secretion of airway epithelium. 2015 Auris Nasus Larynx pmid:25769240
Nayyar E and Taimur S Sporotrichoid lesions: an age-old conundrum. 2015 Am. J. Med. pmid:26021809
Harb AH et al. Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. 2015 Aliment. Pharmacol. Ther. pmid:26011564
Nonaka L et al. Novel macrolide-resistance genes, mef(C) and mph(G), carried by plasmids from Vibrio and Photobacterium isolated from sediment and seawater of a coastal aquaculture site. 2015 Lett. Appl. Microbiol. pmid:25765542
Rose SJ et al. Mycobacterium avium Possesses Extracellular DNA that Contributes to Biofilm Formation, Structural Integrity, and Tolerance to Antibiotics. 2015 PLoS ONE pmid:26010725
Srivastava AK et al. In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation. 2015 Arch. Pharm. (Weinheim) pmid:25996140
Koh WJ et al. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. 2015 Antimicrob. Agents Chemother. pmid:25987622
Tsunemine H et al. [Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)]. 2015 Gan To Kagaku Ryoho pmid:25981655
Ribaldone DG et al. Efficacy of amoxycillin and clarithromycin-based triple therapy for Helicobacter pylori eradication: a 10-year trend in Turin, Italy. 2015 Panminerva Med pmid:25971330
Thellin O et al. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media. 2015 Int. J. Antimicrob. Agents pmid:25963337
Hwang JJ et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. 2015 World J. Gastroenterol. pmid:25945019
Kesselheim AS et al. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. 2015 J Gen Intern Med pmid:25855479
Gianni C Treatment and prevention of paronychia using a new combination of topicals: report of 30 cases. 2015 G Ital Dermatol Venereol pmid:25854670
Zhang S et al. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. 2015 Cancer Lett. pmid:25853150
Zhang S and Long C Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm. 2015 J. Pediatr. Hematol. Oncol. pmid:25851555
Burton AJ et al. Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. 2015 Antimicrob. Agents Chemother. pmid:25824218
Kazama I et al. Macroscopic haemoglobinuria associated with Mycoplasma pneumoniae infection successfully treated by clarithromycin. 2015 Infez Med pmid:25819056
Silva JT et al. Mycobacterium abscessus pulmonary infection complicated with vertebral osteomyelitis in a heart transplant recipient: case report and literature review. 2015 Transpl Infect Dis pmid:25816889
Sugawara M et al. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan. 2015 J. Dermatol. pmid:25809502
Andrianov M et al. A 15-year-old boy with abdominal pain, growth retardation, and anemia secondary to Helicobacter pylori-associated peptic ulcer. 2015 Pediatr Ann pmid:25806733
Zhao C et al. [Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012]. 2015 Zhonghua Jie He He Hu Xi Za Zhi pmid:25791651
Molina-Infante J et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. 2015 Aliment. Pharmacol. Ther. pmid:25776067
Takahashi C et al. Observation of antibacterial effect of biodegradable polymeric nanoparticles on Staphylococcus epidermidis biofilm using FE-SEM with an ionic liquid. 2015 Microscopy (Oxf) pmid:25757698
Metanat HA et al. Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial. 2015 Helicobacter pmid:25752357
Zhou Z et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. 2015 Antimicrob. Agents Chemother. pmid:25451048
Hur J et al. Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. 2015 Chem. Res. Toxicol. pmid:25811541
Streetman DS and Stout SM Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4? 2015 CMAJ pmid:25646282
Ang TL et al. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. 2015 J. Gastroenterol. Hepatol. pmid:25639278
Kimko H et al. Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen. 2015 J Clin Pharmacol pmid:25639255
Berry AC et al. Not All Helicobacter Are pylori. 2015 Clin. Gastroenterol. Hepatol. pmid:25638590
Dinca EB et al. The dangers of gastritis: a case of clarithromycin-associated brief psychotic episode. 2015 J. Nerv. Ment. Dis. pmid:25629665
Liu Q et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection. 2015 Eur J Gastroenterol Hepatol pmid:25629566
Genc G et al. Does systemic clarithromycin therapy have an inhibitory effect on tympanosclerosis? An experimental animal study. 2015 J Laryngol Otol pmid:25619629
Winkel P et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. 2015 Int. J. Cardiol. pmid:25602299
Trespalacios AA et al. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. 2015 Diagn. Microbiol. Infect. Dis. pmid:25600075
Galvidis I et al. Group determination of 14-membered macrolide antibiotics and azithromycin using antibodies against common epitopes. 2015 Anal. Biochem. pmid:25256165
Yoshida S et al. Investigation of the population structure of Mycobacterium abscessus complex strains using 17-locus variable number tandem repeat typing and the further distinction of Mycobacterium massiliense hsp65 genotypes. 2015 J. Med. Microbiol. pmid:25596119
Siekmeier R et al. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. 2015 Adv. Exp. Med. Biol. pmid:25252902
Ontsira Ngoyi EN et al. Molecular Detection of Helicobacter pylori and its Antimicrobial Resistance in Brazzaville, Congo. 2015 Helicobacter pmid:25585658
Spaniol V et al. Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response. 2015 Antimicrob. Agents Chemother. pmid:25583725
Chu HS et al. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense. 2015 PLoS ONE pmid:25581038
Kim H et al. Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. 2015 Ann. Hematol. pmid:25501820
Phan TN et al. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. 2015 Int. J. Antimicrob. Agents pmid:25499186
Adebisi AO et al. Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori. 2015 J. Pharm. Pharmacol. pmid:25496042
Tsay FW et al. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. 2015 Helicobacter pmid:25495272
Mourad-Baars PE et al. Low antibiotic resistance of Helicobacter pylori in The Netherlands. 2015 Helicobacter pmid:25495199
Frija-Masson J et al. [Non-tuberculous mycobacterial infection of a totally implanted perfusion device]. 2015 Rev Mal Respir pmid:25480387
Lee H et al. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. 2015 Dig Liver Dis pmid:25467826
Kobayashi M et al. A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy. 2015 Int. J. Cardiol. pmid:25464498
Dierig A et al. Antibiotic treatment of pertussis: are 7 days really sufficient? 2015 Pediatr. Infect. Dis. J. pmid:25247586
Zhang Y et al. Helicobacter pylori, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. 2015 Carcinogenesis pmid:26449252
Mailleux M et al. Unusual pulmonary toxicity of ipilimumab treated by macrolides. 2015 Acta Clin Belg pmid:26790556
Gisbert JP et al. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. 2015 Dig. Dis. Sci. pmid:25236423
Ersal T et al. Fatal disseminated infection with Fusarium petroliphilum. 2015 Mycopathologia pmid:25234793
Jesus FP et al. In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. 2015 Antimicrob. Agents Chemother. pmid:26459895
Higuchi K et al. Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, multicenter study. 2015 Gastric Cancer pmid:25098924
Hsu PI et al. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. 2015 Medicine (Baltimore) pmid:26632893
Basyigit S et al. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study. 2015 Bosn J Basic Med Sci pmid:26614852
Baumann M et al. Aquatic toxicity of the macrolide antibiotic clarithromycin and its metabolites. 2015 Chemosphere pmid:25051235
Shin SH et al. Helicobacter pylori Eradication Prevents Metachronous Gastric Neoplasms after Endoscopic Resection of Gastric Dysplasia. 2015 PLoS ONE pmid:26580072
Desai S et al. The Epidemiology of Invasive Haemophilus influenzae Non-Serotype B Disease in Ontario, Canada from 2004 to 2013. 2015 PLoS ONE pmid:26569613
Kakked GA et al. Pneumobilia with gastric outlet obstruction. 2015 BMJ Case Rep pmid:26552878
Kim SE et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. 2015 Korean J. Intern. Med. pmid:26552455
Rose WE et al. Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination. 2015 Pharm. Res. pmid:24934663
Nishizawa T et al. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. 2015 J. Clin. Gastroenterol. pmid:24921211
Buch T and Andersen SE [Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval]. 2015 Ugeskr. Laeg. pmid:26471025
Wu IT et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. 2015 World J. Gastroenterol. pmid:26457027
Boyanova L et al. Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance. 2015 Int. J. Antimicrob. Agents pmid:26453146
Rubio M et al. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex. 2015 PLoS ONE pmid:26448181
Blair PW et al. DRESS syndrome presenting after initiation of mycobacterium avium complex osteomyelitis treatment. 2015 BMJ Case Rep pmid:26438676
Barni S et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. 2015 J Investig Allergol Clin Immunol pmid:25997306
Zhi D et al. The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides. 2015 Eur J Pharm Sci pmid:25976224
Vliegenthart AD et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. 2015 Sci Rep pmid:26489516
Zhang W et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. 2015 Gut pmid:26338726
Fasciana T et al. Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily. 2015 J. Med. Microbiol. pmid:26338221
Curth HM et al. Effects of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: Results from a Retrospective Cohort Study. 2015 Am J Clin Dermatol pmid:26334425
Zhu YC et al. Rapid prediction of inducible clarithromycin resistance in Mycobacterium abscessus. 2015 Mol. Cell. Probes pmid:26334290
Georgopoulos SD et al. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. 2015 Expert Opin Pharmacother pmid:26330278
Koide T et al. Analysis of Distribution of Ingredients in Commercially Available Clarithromycin Tablets Using Near-Infrared Chemical Imaging with Principal Component Analysis and Partial Least Squares. 2015 Chem. Pharm. Bull. pmid:26329859
Nozawa K et al. Effect of surfactants or a water soluble polymer on the crystal transition of clarithromycin during a wet granulation process. 2015 Int J Pharm pmid:26325306
Renvoisé A et al. Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. 2015 Antimicrob. Agents Chemother. pmid:26324275
Dingemanse C et al. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. 2015 Carcinogenesis pmid:26320104
Obregón-Henao A et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. 2015 Antimicrob. Agents Chemother. pmid:26303795
Pea F et al. Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. 2015 Transpl Infect Dis pmid:26296391